Nehal Bhatt, MD
Pulmonary Disease · Athens, GANPI 1255406377
Payments from drug & device makers
Across 412 payments — averaging $900.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$318K
- Mylan Specialty L.p.$19K
- United Therapeutics Corporation$17K
- Boehringer Ingelheim$12K
- Viatris Specialty LLC$3K
- Insmed, Inc.$463
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$320,94187%
- Travel & lodging$42,56211%
- Food & beverage$7,1682%
- Education$3020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 246 | $318,002 |
| Mylan Specialty L.p. | 21 | $18,644 |
| United Therapeutics Corporation | 25 | $17,015 |
| Boehringer Ingelheim | 19 | $11,902 |
| Viatris Specialty LLC | 4 | $3,408 |
| Insmed, Inc. | 18 | $463 |
| Actelion Pharmaceuticals US, Inc. | 16 | $286 |
| Grifols USA, LLC | 15 | $209 |
| AstraZeneca | 15 | $206 |
| Intuitive Surgical | 2 | $168 |
| Harmony Biosciences LLC | 3 | $123 |
| Merck | 5 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Sunovion Pharmaceuticals Inc. | 3 | $51 |
| AbbVie | 3 | $46 |
| Noctrix Health, Inc. | 1 | $38 |
| Advanced Respiratory, Inc | 2 | $29 |
| Sanofi | 1 | $27 |
| Genentech USA, Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Resmed Corp | 1 | $20 |
| Shionogi Inc | 1 | $20 |
| Novartis | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$141,558
- TRELEGY ELLIPTA$101,114
- Yupelri$21,890
- NUCALA$19,805
- ORENITRAM$12,900
- TYVASO$9,240
- REMODULIN$9,240
- OFEV$5,454
- Da Vinci Surgical System$107
How this compares
$370,973 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 22 | $517,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 225 | $206,538 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $148,529 |
| XolairOmalizumab | 12 | $100,025 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $83,972 |
| Breo ElliptaFluticasone/Vilanterol | 153 | $67,320 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 115 | $62,818 |
| Ambrisentan | 25 | $58,306 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 90 | $51,155 |
| AdcircaTadalafil | 12 | $48,663 |
| Dupixent SyringeDupilumab | 13 | $48,175 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $33,721 |
| Tadalafil | 15 | $22,176 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $13,413 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $10,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $318,002 | $345,466528 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $61 | $148,52913 claims |
| Grifols USA, LLCProlastin C | $209 | $83,97211 claims |
| Boehringer IngelheimStiolto Respimat | $11,902 | $51,15590 claims |
| United Therapeutics CorporationAdcirca | $17,015 | $48,66312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $206 | $44,56873 claims |
| Johnson & JohnsonXarelto | $25 | $8,33314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Athens
- Karan JulkaAthens$94K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.